Our customers say Excellent
4.8 out of 5 based on 9701 reviews
  • Germany imports four strains of medicinal cannabis from Canada.

    Germany imports four strains of medicinal cannabis from Canada
    Germany imports four strains of medicinal cannabis from Canada

    For some years, German cannabis patients have been able to purchase cannabis flowers from the Netherlands via German pharmacies with a special permit. From the end of August they will also be able to buy four tribes from Canada.

    Germany imports four varieties of medicinal cannabis from Canada.

    The number of cannabis patients in Germany is increasing rapidly and imports from the Dutch cannabis program do not meet the needs of patients. Medical flowers from Canada will soon be available in Germany. Nevertheless, this can only be a temporary solution until Germany commits itself to cultivating cannabis as medicine.

    German cannabis patients were able to acquire cannabis flowers from the Netherlands via German pharmacies with a special permit for the last few years. The imported medicine is quite expensive and because it is not covered by the health insurance, at € 15.00 + x / gram the official "medicinal cannabis flowers" are very expensive. Despite their approval, many of the nearly 800 other cannabis patients in Germany depend on the cheaper black market or their grow box. In Germany, there is still a long way to go before there are effective standard care regimes, whether patients suffer from "just" a painful, chronic disease or when their disease could progress or even be deadly, without cannabis for many years the German government has not introduced a corresponding policy for medical cannabis; Current imports from the Netherlands were approved only by a small number of patients under light pressure, and the arrangement was incomplete and far too expensive from the outset. What you can get for € 7.00 in the Netherlands, costs from € 15.00. Many of the 800 patients are involved in the Cannabis Medicine Self-Help Network (SCM) and for years they have made much better suggestions when it comes to standard provisions for the care of cannabis patients. Self-production, for example. In April 2016, after 17 years and a series of lawsuits, MS patient Michael F. was exceptionally entitled to grow his own cannabis grass @ home. However, this was only a case by case decision that is not true for everyone. In addition, it is still missing that F. in this possession of the Federal Administrative Court in his possession, the valid judgment of the state, in this case by the Federal Institute for Drugs and Medical Devices (BfArM), still missing. For this reason, the patient F. is not yet able to grow his own medicine, four months after the Supreme Court ruling.

    State-controlled cultivation in Germany, which the Federal Ministry of Health has recently planned, has been on the patients' wish list for many years, but was only initiated after the Ministry's verdict and therefore saw no other alternative.

    Nevertheless, a long-term proposal was fulfilled with the import of Canadian cannabis flowers. As of the end of August, "Argyle" and "Princeton" will be available to two tribes from the Canadian cannabis program. Two more tribes, "Penople" and "Houndstooth", will follow. The four tribes are referred to as "Nordle", "Ghost Train Haze", "CBD Skunk Haze" and "Super Lemon Haze" in the US stores and on the Canadian black market, which is set to disappear.

    But before you can buy the new strains, cannabis patients will have to renew their special permit to include the four strains by asking their doctor to complete this form. As soon as the German federal emblem "Adler" has been issued, which is expected at the end of August, the barriers to smoking the first legal "medical" joints from abroad will disappear

    Canada offers its patients more than 200 strains

    In Canada, patients can choose from more than 200 strains, whereas in Germany only six are. More importantly, the capacity that is missing in the Netherlands and still needs to be developed in Germany is available in Canada.
    In Vancouver, Toronto and Montreal, there is much more focus on methods of analysis. Not only the two main active ingredients THC and CBD are measured there; Some companies are voluntarily a "cannabinoid profile" and can thus use other ingredients such as THC-V more effectively. As such, the availability of a variety of strains, including a variety of cannabinoids and terpenes, is extremely important in the case of medicinal cannabis. In Canada, unlike the Netherlands or Germany, this has already been achieved by "Health Canada", the authority responsible for cultivation. However, even if all of the more than 200 Canadian strains were soon available in the pharmacy, they would be even more expensive than medical cannabis, which could be grown here under the same conditions.

    Meanwhile, in Canada 34 companies produce cannabis and some of them are listed on the stock exchange. In California, "medical" cannabis has been the top crop for years - the nation's largest agricultural product. Now the Federal Ministry of Health has decided to move forward and import something that has already been produced domestically, with a little flexibility, vision and understanding of the economy. In Munich there was once a company, "South Hemp", which had produced medicinal cannabis for research purposes. It was not allowed to deliver his product to the patients, though, and had to close because he was unable to sell his product.

    Patients in Germany look forward to the buds shipped from abroad; maybe they could even be a bit cheaper, tastier and even more effective against chronic pain, ADHD or countless other symptoms than Dutch medical cannabis. But German flowers would definitely be just as good, much cheaper, would create jobs, generate taxes and save a lot of CO2. The current requirement of the permit holder already equals half a ton * and is increasing. Once the complicated special approval procedure is replaced by a simple anesthetic effective from 2017, all experts expect an accelerated increase in the number of patients. In Canada, where it is, as it already is, there are currently 54,000 patients from a population of 35 million. Translated to Germany, that would be almost 100,000. The Canadian government even estimates that up to 400,000 Canadian drugs will be approved by 2024. Canadian producers know that, and from now on they calculate and trade a little faster than the German authorities